manufacturing Of estradiol vaginal tablets.
Not Applicable
- Conditions
- Atrophic vaginitis.Senile (atrophic) vaginitis
- Registration Number
- IRCT201309298022N2
- Lead Sponsor
- Vice – Chancellery of Research & Technology Affairs, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 42
Inclusion Criteria
inclusion criteria: Female; having atrophic vaginitis; approved by gynecologist
exclusion sriteria: cervicitis; cervical dysplasia; Bacterial Vaginitis; visible cervical lesions; patients treated with oral estrogen.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dysparenuia. Timepoint: Before and three months after intervention. Method of measurement: Satisfaction questionnaire based on VAS.;Vaginal discharge. Timepoint: Before and three months after intervention. Method of measurement: Satisfaction questionnaire based on VAS.;Vaginal dryness. Timepoint: Before and three months after intervention. Method of measurement: Satisfaction questionnaire based on VAS.;Vaginal irritation. Timepoint: Before and three months after intervention. Method of measurement: Satisfaction questionnaire based on VAS.
- Secondary Outcome Measures
Name Time Method Headaches. Timepoint: Before and three months after intervention. Method of measurement: Satisfaction on VAS.;Nausea. Timepoint: before and three months after intervention. Method of measurement: Satisfaction on VAS.;Vaginal bleeding. Timepoint: before and three months after intervention. Method of measurement: Satisfaction on VAS.